How would you approach incorporating immunotherapy in neoadjuvant treatment for GE junction and gastric cancer?
Patients with deficient mismatch repair (dMMR) and microsatellite instability high (MSI-H) harbor high tumor mutational burden which tends to have favorable response rates to immune checkpoint inhibitors.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · UH Seidman Cancer Center, Case Western Reserve University
Answered on
Neoadjuvant immunotherapy is a reasonable option for patients with locally advanced dMMR/MSI-H esophagogastric cancer. The recently published GERCOR NEONIPIGA study provides some preliminary data. Among the patients who underwent surgery following neoadjuvant immunotherapy, 59% of patients achieved ...
Join for free or sign in to see the full answer